Kristina

Senior Drug Manager, Cardiology Business Unit

Almost one in ten in Russia suffers from chronic heart failure, but not everyone knows about it. I am proud that in my role I can raise awareness of the disease, and the use of digital technologies allows to reach more patients.

Svetlana

Head of Medical Consultants

Over 14 years. I became a doctor to help people. By joining Novartis, I can help fight cancer for far more patients than in practical medicine.

Julia

Head of the Department of Clinical Research of Pharmaceuticals

More than 2000 Russian patients participate in international clinical research. I am proud to work for a company that invests in the development of innovative drugs that change patients' lives for the better.

Vladimir

Research Director

5 positions in 3 countries in 9 years. Working with an innovative portfolio of medicines and great career opportunities inspire me to continue working at Novartis.

Love

Head of Human Resources Department

15 years in the company. During this time, I managed to change 6 positions and gain experience in all divisions. I am pleased to be a member of the HR team. I am here to create an environment in which our employees reach their potential and change the way they approach medicine for the benefit of our patients.

Olga

Senior Regional Manager of the Department for the Promotion of Cardiology Products

The number of patients with cardiovascular diseases that we help is measured in thousands.
I am inspired by the fact that with my daily work I help them to increase the duration and improve the quality of life.

Anna

Head of Department Neurology

Over 5 years with Novartis. The scale and resources of the company allow us to provide more patients with the therapy they need, while at the same time giving us the opportunity to develop in a culture of support and cooperation. This is one of the reasons that inspires me to work at Novartis.

Julia

Director of the Ophthalmic Business Unit

More than 3 years at Novartis I never tire of being proud of what a great company I work for! It is important for us to reveal the talent of each employee. Novartis has a very special atmosphere in which you want to grow and become better!

Rami Sandoz is a highly effective medicinal product, developed by the well-known pharmaceutical company Sandoz GmbH.

It is prescribed both in complex and self therapy arterial hypertension and chronic heart failure, as well as in order to prevent myocardial infarction in coronary disease hearts.

The main active ingredient is ramipril, an active antihypertensive substance from the group of ACE inhibitors.

Presented in the form of tablets, this medication is intended for daily use during the course determined by the doctor.

Detailed information about Rami Sandoz will be useful for anyone who is going to take this drug.

Composition and form of release

The active ingredient in Rami Sandoz is ramipril. It is a highly effective antihypertensive agent belonging to the category of angiotensin-converting enzyme inhibitors and widely used in the treatment of diseases. of cardio-vascular system.

Also in the composition there are auxiliary components:

• microcrystalline cellulose;
• pregelatinized starch;
• precipitated dioxide;
• iron oxide yellow;
• red iron dioxide.

This medication is available in the form of tablets containing various dosages active substance - 0.0025 g, 0.005 g and 0.01 g.

pharmachologic effect

As a result of the use of the drug Rami Sandoz, the distal resistance of the walls of the arteries is significantly reduced.

In patients with severe symptoms of arterial hypertension, there is a decrease in blood pressure. At the same time, the heart rate does not increase.

In most cases, patients stabilize the pressure after 60-120 minutes from the moment of taking the medicine. And after 4-5 hours, the maximum therapeutic effect is achieved, which persists for the next 24 hours.

After 21-30 days, subject to regular use of the drug, the maximum therapeutic effect is achieved.

Indications for use

Rami Sandoz tablets are prescribed in the presence of the following diseases and conditions:

• severe initial or glomerular stage of nephropathy, which may or may not be associated with diabetes mellitus;
• heart failure, which is a consequence of myocardial infarction;
• diabetes mellitus, accompanied by one or more risks of developing cardiovascular diseases (smoking, high blood pressure, high total cholesterol);
• peripheral vascular disease;

This drug is often prescribed for coronary heart disease to effective prevention heart attacks and strokes.

Mode of application

To achieve optimal therapeutic effect you need to take the drug Rami Sandoz every day strictly at a certain time.

You can take the medicine both before and after eating, as this does not affect the process of its absorption.

One tablet should be swallowed whole, without sucking or chewing. Only in some cases is it permissible to divide the tablet into two equal parts. Be sure to drink plenty of fluids.

Depending on the age of the patient, the symptoms of the disease and some other factors, daily dosages may vary.

In the treatment of arterial hypertension, an initial dose of 2.5 mg of the drug per day is prescribed, however, as necessary, it can be doubled after every 2-4 weeks of administration.

In some cases, instead of increasing the dosage, calcium antagonists and diuretics, which are characterized by a slight hypertensive effect, are prescribed simultaneously with Rami Sandoz tablets. As a maintenance dosage, 2.5 to 5 mg of the drug per day is usually prescribed. The maximum allowable dosage for adult patients is 10 milligrams.

Patients who suffer from chronic heart failure are prescribed the drug in an amount of 1.25 mg once a day. However, if at this dosage it is not possible to achieve the desired therapeutic effect, it can be doubled after 1-2 weeks. When prescribing a dosage of 2.5 mg, it can be divided into two doses.

In the post-infarction state, it is necessary to take the drug at a dosage of 2.5 mg twice a day in the first 48 hours. The duration of the course of treatment is three days. If the indicated dose is difficult to tolerate by the patient, it is reduced to 1.25 mg in the first two days, and then increased every 1-3 days of admission.

In the treatment of diabetic or non-diabetic nephropathy, an initial daily dosage of 1.25 mg of the drug is prescribed. Then, after every two days, the dosage is recommended to be doubled until the optimal maintenance level of 5 mg is reached.

In order to prevent myocardial infarctions and strokes, as well as to reduce the risk of mortality as a result of the development of diseases of the cardiovascular system, the following dosages are prescribed: for 1-2 weeks once a day, 2.5 mg of the drug, and then every 2-3 weeks it must be increased to a maintenance level of 10 mg per day.

In the treatment of renal failure, the daily dosage of the drug is prescribed to the patient individually, depending on the creatinine clearance.

Interaction with other drugs

Before you start taking Rami Sandoz, it is important to consider the features of its interaction with other drugs.

The hypotensive effect of these tablets is enhanced if they are taken together with other antihypertensive drugs, as well as anesthetics, tricyclics, antipsychotics, and drugs containing opium.

The hypotensive property of Rami Sandoz is reduced when it is taken simultaneously with anti-inflammatory drugs. nonsteroidal drugs(aspirin, indomethacin, etc.), sympathomimetics, drugs with estrogen, as well as drugs and foods that contain salt.

As a result of taking the drug together with medicines containing potassium, the concentration of this element in the blood serum increases significantly.

Simultaneous use with drugs belonging to the categories of immunosuppressants, corticosteroids and cytostatics leads to an increased risk of leukopenia.

When combining Rami Sandoz tablets with drugs intended for the treatment diabetes may increase the hypoglycemic effect.

Side effects

Side effects

The immune system	unidentified - increased levels of anti-nuclear antibodies, anaphylactoid and anaphylactic reactions.
CCC	often - syncope, orthostatic decrease in blood pressure, arterial hypotension; infrequently - myocardial ischemia, including myocardial infarction or angina pectoris, tachycardia, palpitations, arrhythmia, hot flashes, redness, peripheral edema; rarely - vasculitis, hypoperfusion, vascular stenosis; extremely rarely - ischemic stroke, short-term ischemic attack; unidentified - Raynaud's syndrome.
Nervous system	often - dizziness, headaches; infrequently - paresthesia, dysgeusia, vertigo, ageusia; rarely - imbalance, tremor; unidentified - cerebral ischemia, incl. transient ischemic attack and ischemic stroke, heartburn, impaired psychomotor functions, parosmia.
Hematopoietic system	rarely - a decrease in the number of white cells (including agranulocytosis and neutropenia), a decrease in the number of red cells, a decrease in the number of platelets, a reduced level of hemoglobin; infrequently - eosinophilia; unidentified - hemolytic anemia, pancytopenia, bone marrow failure.
hearing organ	rarely - ringing in the ears, hearing loss.
mental disorders	infrequently - anxiety, anxiety, mood changes, sleep disturbance (including somnolence), nervousness; rarely - confusion; unidentified - impaired attention.
Organ of vision	infrequently - problems with vision, including its blurriness; rarely - conjunctivitis.
Respiratory system	often - sinusitis, bronchitis, unproductive cough; infrequently - nasal congestion, bronchospasm, including exacerbation of asthma; rarely - dyspnea.
digestive tract	often - inflammation in the digestive tract and oral cavity, abdominal discomfort, indigestion, diarrhea, vomiting, dyspepsia, nausea; infrequently - increased levels of pancreatic enzymes, pancreatitis, angioedema of the small intestine, pain in the upper abdomen, dry mouth, constipation, gastritis; rarely - a feeling of discomfort in the abdominal cavity, glossitis, stomach pain; unidentified - aphthous stomatitis.
Metabolic disorders	often - an increase in the level of potassium in the blood; infrequently - loss of appetite, anorexia; unidentified - a decrease in the level of sodium in the blood.
Hepatobiliary disorders	infrequently - an increase in the level of bilirubin conjugates and / or liver enzymes; rarely - damage to liver cells cholestatic jaundice; unidentified - cytolytic or cholestatic hepatitis, acute liver failure.
reproductive system	infrequently - decreased libido, transient erectile impotence; unidentified - gynecomastia.
urinary system	infrequently - violation renal function, including acute renal failure, worsening of underlying proteinuria, an increase in the amount of urine, an increase in creatinine and blood urea levels.
Leather	often - rash (for example, maculopapular), urticaria, itching; infrequently - angioedema (in exceptional cases, angioedema leads to impaired patency respiratory tract, which is fatal), hyperhidrosis; rarely - onycholysis, urticaria, exfoliative dermatitis; unspecified - toxic epidermal necrolysis, erythema multiforme, exacerbation of psoriasis, alopecia, pemphigus, Stevens-Johnson syndrome, lichenoid or pemphigoid exanthema or enanthema, pemphigus, psoriatic dermatitis; extremely rarely - a photosensitivity reaction.
General disorders	often - asthenia, chest pain; rarely - fatigue, drowsiness, weakness; infrequently - pyrexia.
Musculoskeletal apparatus	often - myalgia, muscle spasms; infrequently - arthralgia.
Endocrine disorders	unidentified - the development of a syndrome of inappropriate secretion of antidiuretic hormone.

Despite such an extensive list side effects, in practice they happen extremely rarely - as a rule, as a result of non-compliance with the rules for taking the drug.

Overdose

Reception above the permissible dose of the drug is fraught with such consequences as hypotension and arterial collapse, slowing of the heart, impaired natural kidney function, as well as impaired electrolyte metabolism.

Contraindications

Rami Sandoz tablets are contraindicated in a certain number of conditions, including:

• individual intolerance to the components or excessive sensitivity to them;
• arterial hypotension;
• Availability angioedema in history;
• severe renal failure;
• primary hyperaldosteronism;
• hemodynamic instability;
• unilateral or bilateral stenosis of the renal artery;
• childhood.

During pregnancy

During pregnancy and lactation, the use of the drug Rami Sandoz is contraindicated. If the patient becomes pregnant during the course of treatment, it is necessary to immediately stop further taking these tablets.

Alternatively, the doctor should prescribe therapy without the use of ACE inhibitor drugs.

Terms and conditions of storage

The medicine can be stored for two years. The main thing is that the packaging is original, and the temperature in the room does not exceed 25 degrees.

Price

Rami Sandoz is a prescription drug. Its average cost in Russian pharmacies ranges from 200 to 630 rubles.

Most pharmacies on the territory of Ukraine you can buy Rami Sandoz tablets for about 70-150 hryvnias.

Analogues

The most effective analogues of the drug Rami Sandoz, which have the same active ingredient, include:

In addition, there are several analogues characterized by identical action and method of application. Among them:

• Hiten;

Before choosing the most the best option it is recommended to consult a doctor.

Russia is one of the most significant markets for Sandoz. The strong position of our drugs, based on their high quality and reputation, the optimal price and a wide range of generic applications, allow the company to occupy a strong position among the leaders of the Russian pharmaceutical industry.

We are proud of the consistently high quality of Sandoz medicines, which are produced for Russia at the largest pharmaceutical factories in Europe. The optimal price and availability of drugs is due to the fact that innovative solutions and innovative technologies are used for their production.

The range of Sandoz products in Russia includes all major therapeutic groups. Among the most important are antibiotics (anti-infective drugs), drugs used for violations of the central nervous systems s, drugs for the treatment of diseases gastrointestinal tract, drugs for the treatment of cardiovascular diseases, drugs for the treatment of diseases of the musculoskeletal system, iron preparations for the treatment of anemia, immunomodulators, basic chemotherapy drugs. An important place in the portfolio is occupied by OTC drugs (OTC): Linex®, ACC®, Exoderil®, Baneocin®, Immunal®, etc.

We work closely with pharmacies, healthcare institutions and doctors, sharing experience in the fight against various diseases and provide doctors with the most up-to-date information they need when working with patients. We not only produce and sell medicines, but we also actively participate in the scientific and practical life of Russian healthcare.

The Memorandum of Intent signed by Novartis with the City of St. Petersburg to build a full-scale, full-cycle manufacturing facility represents an important step forward for the company's operations in Russia. With a capacity of approximately 1.5 billion units per year, this plant is expected to produce both brand new innovative drugs and high-quality generics. Most of the expected production volume will be generics, which will significantly increase Sandoz's ability to distribute our medicines to Russian patients, helping to strengthen the local healthcare system and improve patient outcomes in Russia.

As a global company, Sandoz is committed to helping society wherever it operates.

Every year, as part of the "Social Partnership Day" - a charity event in which Novartis Group companies around the world take part - our employees support those who need it most. In Russia, Sandoz has been helping orphanages and orphanages in Moscow and the Moscow Region for several years. We plan to expand the geography of the company's charitable assistance in the regions of Russia.

Company Sandoz, the generics division of the Novartis group of companies, is a leader in the rapidly growing generics industry. Sandoz offers about 1,100 high-quality, affordable drugs that are out of patent protection. With over 26,000 employees in 140 countries Sandoz occupies a leading position in the world both in the field of biosimilars, in the market for injectable, ophthalmic, dermatological drugs, as well as 5th place among manufacturers of inhaled drugs. The group of the company's most significant pharmaceutical products includes antibiotics, medicines for the treatment of diseases of the cardiovascular and central nervous systems, the gastrointestinal tract, and hormone therapy. Company Sandoz develops, manufactures and markets medicines, as well as pharmaceutical, biotechnological active ingredients and antibiotics. In addition to strong growth in recent years, the company Sandoz made a number of acquisitions, including Lek (Slovenia), Sabex (Canada), Geksal (Germany), Eon Labs (USA), Ebewe Pharma (Austria), Oriel Therapeutics (USA) and Fugera Pharmaceuticals (USA). In 2012, net sales reached US$8.7 billion.

Main therapeutic areas

Anti-infectives

The cardiovascular system

Blood and hematopoietic organs

Digestive system and endocrinological disorders

central nervous system

Anticancer and immunomodulatory agents

Respiratory system

Dermatological products

Ophthalmic products

A differentiated portfolio of drugs provides additional benefits

Biosimilars – high-quality, clinically proven alternatives to existing biologics with comparable safety and efficacy at a more affordable price. Sandoz is a pioneer and world leader with three marketed products that are top sellers in their therapeutic areas (G-CSF, EPO, Human Growth Hormone).

Injectable drugs - non-biological drugs, administered by injection, which are available modern generic drugs. Company Sandoz ranked first in this field since 2011.

Inhalation drugs – sophisticated drugs and high-tech delivery devices to meet the rapidly growing demand for affordable new drugs for treatment bronchial asthma and COPD (chronic obstructive pulmonary disease) in a complex regulatory environment. Company Sandoz strive to take a leading position in this direction in order to further strengthen its position along with other strategic directions.

Ophthalmic preparations - high-quality medicines aimed at correcting anatomical, physiological conditions and fighting eye diseases. With the acquisition a wide range Generic Ophthalmic Products Division Falcon Company Sandoz has become a world leader in this field.

Dermatological preparations - drugs based on rich experience in development and production and intended for the treatment of dermatological diseases, including drugs in semi-liquid forms (creams and ointments), as well as more than 60 FDA (Food and Drug Administration) approved drug names for various therapeutic groups of the PharmaDerm division in the USA. Through the acquisition of Fuger Pharmaceuticals, the company Sandoz is a world leader in generic dermatological products.